Saturday 17 October 2026 Export SHC’s income statement to Excel — free account

Sotera Health Company

Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024. In the quarter to June 2026, revenue grew 9.18%, EPS grew 533.3%, free cash flow grew 60.6% and total debt fell 3.54%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

17.89 0.18 −1.00%

Follow SHC

Alert me

Market cap: $5.2B
P/E: 31.4×
Fwd P/E: 23.7×
Dividend yield: —
F-score: 7/9
Altman Z: 1.76
Beneish M: −2.75
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1,635.09

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	3	—	—	2	—	2	—	—	2	—	—

Insider Ownership 2.24%

Capital & Financial Ratios $m

Market Cap 5,160.00

Revenue 1,216.17

Net Income 163.48

Free Cash Flow 112.70

Net Debt 1,874.31

Current Ratio 2.80

Debt/Equity 3.35

P/E ratio 31.39

Fwd P/E 23.70

P/S ratio 4.20

P/B ratio 7.68

Past 5Y EPS Growth —

This Y EPS Growth 14.42%

Next Y EPS Growth 9.23%

Next Y revenue growth 7.17%

Next 5Y EPS Growth 11.19%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 8.30%

10-year low 10-year high

P/S against its own 10 years 48.04%

10-year low 10-year high

P/B against its own 10 years 20.41%

10-year low 10-year high

EV/Sales against its own 10 years 37.31%

10-year low 10-year high

EV/FCF against its own 10 years 48.74%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	302	279	346	357
Receivables	153	147	147	159
Inventory	48	49	54	56
Other	—	—	—	83
	557	526	613	646

	2023	2024	2025	Q'26
Payables	71	55	78	101
ST’ Debt	5	15	14	14
Other	—	—	—	—
	231	191	250	231

Compound Annual Growth %

	10y	5y	3y
Sales	—	7.30%	5.05%
Cash Flow	—	18.95%	1.10%
Earnings	—	0.00%	0.00%
Book Value	—	5.92%	20.05%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	280	321	—	—	—
’25	255	294	311	303	1,164
’24	248	277	285	290	1,100
’23	221	255	263	310	1,049
’22	237	267	249	252	1,004
’21	212	252	226	241	931
’20	188	213	200	217	818

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	29	88	—	—	—
’25	56	57	71	103	287
’24	10	61	97	56	224
’23	34	(337)	42	113	(148)
’22	50	58	68	102	278
’21	56	78	81	66	282
’20	6	47	46	22	121

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(17)	42	—	—	—
’25	36	26	35	52	149
’24	(25)	19	61	(10)	45
’23	(11)	(390)	(10)	48	(363)
’22	14	22	29	30	96
’21	35	54	65	25	179
’20	(7)	37	36	2	67

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.09	0.19	—	—	—
’25	(0.05)	0.03	0.17	0.12	0.27
’24	0.02	0.03	0.06	0.04	0.16
’23	0.01	0.08	(0.05)	0.14	0.18
’22	0.11	0.11	0.09	(1.14)	(0.83)
’21	0.04	0.15	0.10	0.13	0.41
’20	(0.01)	0.03	0.00	(0.17)	(0.16)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	24.05	20.48	5.78	8.02	10.71	9.53	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	29.00	30.38	24.90	19.40	17.44	17.83
People
People	Employees	—	—	—	2,900	3,000	3,000	3,000	3,000	3,000	3,000
	Revenue/emp, $m	—	—	0.00	0.27	0.27	0.31	0.33	0.35	0.37	0.39
Income, $m
Income, $m	Revenue	—	—	746	778	818	931	1,004	1,049	1,100	1,164
	Gross margin, %	—	—	47.88	50.81	54.22	55.68	55.50	55.00	54.73	55.48
	EBT	—	—	24	(1)	(39)	176	(243)	106	114	148
	EBT margin, %	—	—	3.25	(0.12)	(4.75)	18.86	(24.22)	10.10	10.35	12.68
	Net income	—	0	(6)	(20)	(37)	117	(234)	51	44	78
	Depreciation	—	—	204	155	155	157	161	167	171	142
Per share, $
Per share, $	Revenue	—	—	3.21	3.35	3.44	3.34	3.58	3.73	3.89	4.10
	Earnings	—	—	(0.03)	(0.09)	(0.16)	0.41	(0.83)	0.18	0.16	0.27
	Cash flow	—	—	0.51	0.64	0.51	1.01	0.99	(0.53)	0.79	1.01
	Capex	—	—	(0.31)	(0.25)	(0.23)	(0.37)	(0.65)	(0.76)	(0.63)	(0.49)
	Free cash flow	—	—	0.20	0.39	0.28	0.64	0.34	(1.29)	0.16	0.53
	Book value	—	—	0.20	(2.76)	1.91	2.10	1.25	1.58	1.43	2.13
	Shares, m	—	—	232	232	238	279	280	281	283	284
Valuation, ×
Valuation, ×	P/E	—	—	4,648.15	4,648.15	0.00	56.07	0.00	93.06	91.20	65.33
	P/S	—	—	7.32	7.32	8.50	7.06	2.32	4.49	3.52	4.30
	P/B	—	—	0.00	0.00	15.30	11.22	6.66	10.61	9.55	8.27
	EV/Sales	—	—	10.94	10.94	10.66	8.87	3.92	6.34	5.37	5.93
	EV/FCF	—	—	55.56	55.56	130.05	46.07	41.20	(18.34)	131.01	46.23
Cash, $m
Cash, $m	Operating cash flow	—	—	120	149	121	282	278	(148)	224	287
	Capex	—	—	(73)	(57)	(54)	(102)	(182)	(215)	(179)	(138)
	Free cash flow	—	—	47	92	67	179	96	(363)	45	149
Balance, $m
Balance, $m	Working capital	—	—	169	128	174	185	(147)	327	335	364
	Total debt	—	—	2,236	2,847	1,871	1,794	2,001	2,249	2,318	2,235
	Net debt	—	—	2,140	2,784	1,768	1,687	1,605	1,947	2,039	1,888
	Shareholders’ equity	—	—	45	(641)	455	586	350	444	405	606
Returns, %
Returns, %	ROA	—	—	(0.43)	(0.79)	(1.45)	4.21	(7.91)	1.64	1.43	2.46
	ROIC	—	—	2.31	5.35	5.79	7.06	7.94	7.23	7.61	9.07
	ROE	—	—	1.96	7.00	41.40	22.46	(49.89)	12.87	10.45	15.42

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
QGEN QIAGEN N.V.	$9.5B	23.6×	17.5×	+0.28% (above 0%: growing)	+7.94% (above 0%: growing)	+30.45% (above 0%: growing)	63.62%	24.75%	Compare
TWST Twist Bioscience Corporation	$9.5B	— (loss-making)	— (loss-making)	+23.24% (above 0%: growing)	n/m	−7.23% (below 0%: shrinking)	52.76%	(30.65%)	Compare
GRAL GRAIL, Inc.	$6.1B	— (loss-making)	— (loss-making)	+25.72% (above 0%: growing)	n/m	−4.95% (below 0%: shrinking)	(28.12%)	(388.89%)	Compare
RDNT RadNet, Inc.	$5.5B	— (loss-making)	279×	+24.99% (above 0%: growing)	−47.37% (below 0%: shrinking)	−43.22% (below 0%: shrinking)	14.14%	6.34%	Compare
SHC Sotera Health Company	$5.2B	31.4×	23.7×	+9.18% (above 0%: growing)	+533.33% (above 0%: growing)	+60.56% (above 0%: growing)	55.38%	33.23%
BLLN BillionToOne, Inc.	$4.9B	95.0×	99.4×	+64.40% (above 0%: growing)	n/m	+400.65% (above 0%: growing)	70.45%	5.03%	Compare
ADPT Adaptive Biotechnologies Corporation	$4.1B	— (loss-making)	— (loss-making)	+21.53% (above 0%: growing)	n/m	+42.04% (above 0%: growing)	71.82%	(22.04%)	Compare
VCYT Veracyte, Inc.	$3.6B	29.9×	45.1×	+15.49% (above 0%: growing)	n/m	+32.95% (above 0%: growing)	72.21%	15.29%	Compare
CDNA CareDx, Inc.	$3.5B	29.7×	2,967×	+52.23% (above 0%: growing)	n/m	+223.42% (above 0%: growing)	73.50%	85.81%	Compare
Median of peers	$5.2B	29.8×	99.4×	+24.12%	—	+31.70%	67.04%	5.69%

All 52 Diagnostics & Research stocks →

Sotera Health Company (SHC) key facts

Strength: Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
Strength: Net income was $77.9 million, or $0.27 per share (basic), a net margin of 6.70%.
Sotera Health Company (SHC) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SHC traded at $17.89, a market capitalization of $5.2 billion.
At that price the stock trades at 31.4× trailing-twelve-month earnings and 4.2× sales; its P/E is higher than 8% of its own readings over the past ten years.
Return on equity was 15.4% and debt-to-equity 3.35.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 1.76 (distress zone) for fiscal 2025.